{
    "clinical_study": {
        "@rank": "146141", 
        "arm_group": [
            {
                "arm_group_label": "Linagliptin 5mg", 
                "arm_group_type": "Experimental", 
                "description": "given once daily over 28 days"
            }, 
            {
                "arm_group_label": "Glimepiride", 
                "arm_group_type": "Active Comparator", 
                "description": "given once daily in 1mg dosis over 7 days, following a titration step to 2mg and application for 21 days"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "given once daily over 28 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The general aim of the present study is to investigate the impact of 4 weeks treatment with\n      linagliptin (5 mg) on endothelial function in patients with type 2 diabetes mellitus. In the\n      current trial this effect of linagliptin treatment on endothelial function will be compared\n      against both the sulfonylurea glimepiride and against placebo, which has not been tested in\n      a trial before; as also is the case for other DPP-4 inhibitors.\n\n      Besides placebo, glimepiride was chosen as a comparator, as it is one compound of the second\n      most used oral antidiabetic drug class."
        }, 
        "brief_title": "Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Diabetes Mellitus, Type 2", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Type 2 diabetic male and female patients according to the following criteria:\n\n             Based upon a complete medical history and clinical laboratory tests\n\n          2. Age >= 18 and Age <= 65 years\n\n          3. Body mass index >= 25 <= 35 kg/m2\n\n          4. HbA1c <= 7.5%\n\n          5. Treatment with metformin (=1500 mg daily) for <= 3 months\n\n          6. Signed and dated written informed consent prior to admission to the study in\n             accordance with GCP and the local legislation.\n\n             For female patients of childbearing potential:\n\n          7. Use of acceptable method of contraception (Pearl-Index <1).\n\n        Exclusion criteria:\n\n          1. Treatment with any glucose-lowering drug except for metformin within prior 3 months.\n\n          2. Any finding of the medical examination (including blood pressure, pulse rate and\n             electrocardiogram) deviating from normal and of clinical relevance.\n\n          3. Any evidence of a clinically relevant acute concomitant disease\n\n          4. History of cardiovascular disease (e.g. coronary artery disease history of acute\n             myocard infarction or stroke, peripheral vascular disease).\n\n          5. History of major diabetic complications (e.g. nephropathy, retinopathy)\n\n          6. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, immunological or\n             hormonal disorders (except: hypertension treated with angiotensin receptor blocker or\n             angiotensin-converting-enzyme inhibitors, hyperlipidemia with statin therapy, thyroid\n             hormone replacement therapy, all stable for at least three months prior to\n             screening).\n\n          7. Surgery of the gastrointestinal tract (except appendectomy).\n\n          8. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or\n             neurological disorders.\n\n          9. History of relevant orthostatic hypotension, fainting spells or blackouts.\n\n         10. Chronic or relevant acute infections.\n\n         11. History of relevant allergy/hypersensitivity (including allergy to drug or its\n             excipients).\n\n         12. Intake of drugs with a long half-life (> 24 hours) within at least one month or less\n             than 10 half-lives of the respective drug prior to administration or during the\n             trial.\n\n         13. Participation in another trial with an investigational drug within one month prior to\n             administration or during the trial.\n\n         14. Smoker (>= 1 cigarettes or >= 1 cigars or >= 1 pipes/day).\n\n         15. Alcohol abuse (more than 60 g/day).\n\n         16. Drug abuse.\n\n         17. Blood donation (more than 100 mL within four weeks prior to administration or during\n             the trial).\n\n         18. Excessive physical activities (within one week prior to administration or during the\n             trial).\n\n         19. Any laboratory value outside the reference range that is of clinical relevance."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01703286", 
            "org_study_id": "1218.105", 
            "secondary_id": "2012-003317-33"
        }, 
        "intervention": [
            {
                "arm_group_label": "Linagliptin 5mg", 
                "description": "Placebo matching Glimepiride", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Linagliptin 5mg", 
                "description": "given once daily for 28 days", 
                "intervention_name": "Linagliptin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Glimepiride", 
                "description": "Placebo matching Linagliptin", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo matching Linagliptin", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo matching Glimepiride", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Glimepiride", 
                "description": "1 mg for 7 days followed by uptitration to 2 mg (given for following 21 days)", 
                "intervention_name": "Glimepiride", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glimepiride", 
                "BI 1356"
            ]
        }, 
        "lastchanged_date": "January 22, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Neuss", 
                    "country": "Germany"
                }, 
                "name": "1218.105.001 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "Randomized, Three Period Cross Over, Double Blind, Double Dummy Study in Type 2 Diabetic Patients to Assess the Endothelial Effects of Linagliptin, Glimepiride and Placebo Therapy for 28 Days ('ENDOTHELINA')", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Ministry of Food, Agriculture and Consumer Protection"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in endothelial function as measured with flow mediated vasodilation (FMD) at baseline (fasting), and on day 28 (fasting)", 
            "safety_issue": "No", 
            "time_frame": "baseline and 4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01703286"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in endothelial independent vasodilation (EIDV) at baseline (2 h post meal), and on day 28 (2 h post meal)", 
                "safety_issue": "No", 
                "time_frame": "baseline and 4 weeks"
            }, 
            {
                "measure": "Number of patients with adverse events", 
                "safety_issue": "No", 
                "time_frame": "up to 20 weeks"
            }, 
            {
                "measure": "Change from baseline in endothelial function as measured with flow mediated vasodilation (FMD) at baseline (2 h post meal), and on day 28 (2 h post meal)", 
                "safety_issue": "No", 
                "time_frame": "baseline and 4 weeks"
            }, 
            {
                "measure": "Number of patients with hepatic injury", 
                "safety_issue": "Yes", 
                "time_frame": "up to 20 weeks"
            }, 
            {
                "measure": "Number of patients with hypersensitivity reactions", 
                "safety_issue": "Yes", 
                "time_frame": "up to 20 weeks"
            }, 
            {
                "measure": "Number of patients with skin lesions", 
                "safety_issue": "Yes", 
                "time_frame": "up to 20 weeks"
            }, 
            {
                "measure": "Number of patients with renal adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 20 weeks"
            }, 
            {
                "measure": "Number of patients with Pancreatitis", 
                "safety_issue": "Yes", 
                "time_frame": "up to 20 weeks"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "collaborator": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}